Revance Emerges Victorious in Merger with Crown Labs, Eyes Aesthetic Medicine Market
Deal News | Jun 02, 2025 | EIN
Revance Therapeutics has announced the completion of its merger with Crown Laboratories. This merger strategically positions Revance to compete with leading companies in the aesthetic medicine industry. By merging resources and expertise with Crown Labs, Revance aims to enhance its position in the highly competitive market, focusing on developing and delivering innovative solutions. The combined entity is poised to leverage synergies and drive growth, with a particular focus on expanding market reach and product offerings in the aesthetic space.
Sectors
- Pharmaceuticals
- Aesthetic Medicine
Geography
- United States – Revance Therapeutics and Crown Laboratories are based in the United States, and the merger impacts the U.S. aesthetic medicine market.
Industry
- Pharmaceuticals – Revance and Crown Labs operate within the pharmaceutical sector, developing and marketing medical and aesthetic solutions.
- Aesthetic Medicine – The merger focuses on strengthening their position within the field of aesthetic medicine, which includes non-surgical treatments and therapies for cosmetics and appearance.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Revance Therapeutics | Bidding Company | Company | A biopharmaceutical company focusing on innovative aesthetic and therapeutic offerings. |
| Crown Laboratories | Target Company | Company | A company specializing in skin care and aesthetic medicine products, merging with Revance to expand market presence. |